3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Active not recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Conditions
Sarcoma
4
Gliosarcoma
4
Glioblastoma
4
Brain Neoplasms
3
Ovarian Neoplasms
2
Oligodendroglioma
2
Breast Neoplasms
2
Urologic Neoplasms
1
Thyroid Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Soft Tissue Neoplasms
1
Sarcoma, Alveolar Soft Part
1
Rhabdomyosarcoma
1
Recurrence
1
Prostatic Neoplasms
1
Platinum-Refractory Fallopian Tube Carcinoma
1
Pharyngeal Neoplasms
1
Pancreatic Neoplasms
1
Osteosarcoma
1
Neurofibromatosis 2
1
Neoplasms, Mesothelial
1
Neoplasms
1
Neoplasm Metastasis
1
Mouth Neoplasms
1
Melanoma
1
Lymphangioleiomyomatosis
1
Liposarcoma
1
Leiomyosarcoma
1
Hemangiosarcoma
1
Glioma
1
Interventions
Doxorubicin
18
Ifosfamide
13
Radiotherapy
8
Paclitaxel
7
pazopanib
6
pembrolizumab
4
Gemcitabine
4
Filgrastim
4
Chemotherapy, Adjuvant
4
Bevacizumab
4
spartalizumab
3
durvalumab
3
Sorafenib
3
Propranolol
3
Nivolumab
3
Ipilimumab
3
Imatinib Mesylate
3
Etoposide
3
Epirubicin
3
Docetaxel
3
Carboplatin
3
trebananib
2
regorafenib
2
cixutumumab
2
cemiplimab
2
carotuximab
2
brostallicin
2
belinostat
2
balstilimab
2
Watchful Waiting
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Hemangiosarcoma
×
Disulfides
×
Sarcoma
×
Clear all
NCT04668300
2026-04-15
DOSa
M.D. Anderson Cancer Center
Phase 2
Active not recruiting
75 enrolled